CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires KWS BioTest Limited
Snapshot
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired KWS BioTest Limited for $20.3 million in cash in January 2018. The transaction was structured as all cash. KWS BioTest Limited is a United Kingdom-based Discovery and Safety Assessment (DSA) business.
- Acquirer
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- Target
- KWS BioTest Limited
- Value
- $20.3 million in cash
- Date
- January 2018
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired KWS BioTest Limited for $20.3 million in cash, a transaction completed in January 2018, structured as all cash.
KWS BioTest Limited operates in Discovery and Safety Assessment (DSA), is based in United Kingdom. KWS BioTest was a CRO specializing in in vitro and in vivo discovery testing services for immuno-oncology, inflammatory and infectious diseases.
The acquisition enhances our discovery expertise, with complementary offerings that provide our customers with additional tools in the active therapeutic research areas of oncology and immunology. The purchase price for KWS BioTest was $20.3 million in cash.
DSA segment, discovery services
No advisory firms have been disclosed for this transaction.